![](https://investorshub.advfn.com/uicon/477075.png?cb=1499007485)
Wednesday, February 19, 2020 11:18:31 PM
Dr. Zeevi received her DVM from the Koret School of Veterinary Medicine, The Hebrew University of Jerusalem and her PhD in microbiology and immunology from the Beer Sheva University. Her roles at NeuroDerm involve leading all internal, out-sourced, and collaborative research activities for the company. These activities include directing and coordinating formulation, optimization, and product development, overseeing analytical and bio-analytical methods, and creating testing for in vitro and in vivo models for the evaluation of safety and efficacy. Dr. Zeevi has over 20 yrs experience in designing and directing research and pharmaceutical development programs. This experience includes GLP-compliant pre-clinical development of small molecule and biological drugs in various indications – including CNS diseases – for the pharmaceutical and biotech industry. She holds 14 patents and patent applications for her inventions, the latest of which forms the basis of NeuroDerm’s current project, ND0611.
Hmmm...I don't think it's possible for this exceptional woman to sit around collecting a salary while doing nothing.
https://www.michaeljfox.org/researcher/oron-yacoby-zeevi-phd-vdm
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM